๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› UK
Clinical trial register · United Kingdom · industry-sponsored

Industry-sponsored studies with a UK investigative site

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2847 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:15 UTC
2847
Studies in scope
industry-sponsored, all four open statuses
1382
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2004 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 416
Narrow the register
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Merck Sharp & Dohme LLC116 Hoffmann-La Roche105 Novartis Pharmaceuticals97 Janssen Research & Development, LLC93
Site city
London2004 Manchester672 Birmingham470 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
2847 of 2847 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
NCT07322003Amyotrophic Lateral Sclerosis
Prilenia
Phase 3
500
London, Stoke-on-Trent
2026-02-01
Not yet open
International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRE
NCT07191548Colorectal Adenocarcinoma Metastatic in the Liver, Liver Ablation, Liver Cancer, Adult
Angiodynamics, Inc.
Not applicable
50
Manchester
2026-02
Not yet open
International Study on Treatment of Liver (HCC) Patients With IRE
NCT07192731Hepatocellular Carcinoma (HCC), Liver Ablation, Liver Cancer, Adult
Angiodynamics, Inc.
Not applicable
50
Manchester
2026-02
Recruiting
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
NCT07080385Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase 2/3
28
London, Manchester
2026-01-30
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
NCT07328451Alzheimer Disease, Early Onset
Denali Therapeutics Inc.
Phase 1
68
London
2026-01-30
Recruiting
A Prospective Multicenter Clinical Investigation Evaluating the Accuracy of the Trimline Design When Treated With SureSmileยฎ Aligners.
NCT07290790Malocclusion
Dentsply Sirona Implants and Consumables
Not applicable
90
Bexleyheath
2026-01-29
Active, closed
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
NCT07344779Metastatic Hormone-Sensitive Prostate Cancer
Bayer
Observational
1,600
Multiple Locations
2026-01-29
Recruiting
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
NCT07323654Eosinophilic Asthma
Kymera Therapeutics, Inc.
Phase 2
264
Bedford, Birmingham, Bristol, Leicester, London, Wythenshawe
2026-01-28
Active, closed
Reconfirming the Safety and Performance of the Glyconics-DS System in Known Populations With and Without Diabetes
NCT07039357Diabetes Mellitus, Healthy
Glyconics Ltd
Not applicable
100
Ashton-under-Lyne, London
2026-01-28
Recruiting
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
NCT07336446Prostate Cancer
AstraZeneca
Phase 1/2
300
Cambridge
2026-01-27
Active, closed
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
NCT07234942Alzheimer's Disease
Hoffmann-La Roche
Phase 1
6
London, Southampton, Glasgow
2026-01-27
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190Uveal Melanoma
IDEAYA Biosciences
Phase 3
520
Metropolitan Borough of Wirral, London, Sheffield
2026-01-25
Recruiting
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
NCT07230288Idiopathic Pulmonary Fibrosis
AbbVie
Phase 2
165
Cambridge, Edinburgh, London, Southampton, Norwich
2026-01-23
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3
500
Birmingham, Bournemouth, Leeds, London, Norwich
2026-01-22
Recruiting
A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults and Adults With FV Leiden or Prothrombin G20210A Mutation
NCT07430397Factor V Leiden, Prothrombin G20210A
City Therapeutics
Phase 1
128
London
2026-01-22
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
Liverpool, London, Manchester, Sheffield
2026-01-22
Recruiting
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
NCT07332091Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
CSL Behring
Phase 2
84
Glasgow, Belfast, Bristol, Liverpool, London, Norwich, Nottingham, Oxford
2026-01-22
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse
CellCentric Ltd.
Phase 2
100
Withington, Sutton, Cardiff, Bebington, Edinburgh, London, Oxford, Southampton
2026-01-22
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
NCT07359846Severe Asthma
Generate Biomedicines
Phase 3
786
High Wycombe, Bristol, London, Romford, Rotherham, Thetford, Nottingham, Somerton
2026-01-20
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703Cervical Cancer
Merck Sharp & Dohme LLC
Phase 3
1,023
Edinburgh, Withington
2026-01-19
Recruiting
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
NCT07053800Lupus Nephritis
Autolus Limited
Phase 2
35
Birmingham, Bristol, Cambridge, Edinburgh, Glasgow, London, Manchester
2026-01-16
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
Boehringer Ingelheim
Phase 3
400
Cardiff, Edinburgh, London, Manchester, Sutton
2026-01-16
Recruiting
Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US
NCT07557498Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol-Myers Squibb
Observational
362
Bollington
2026-01-15
Recruiting
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
NCT07266402Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
Celldex Therapeutics
Phase 3
240
Cambridge, Glasgow, Manchester
2026-01-15
Recruiting
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
NCT06980480Multiple Myeloma, Secondary Immunodeficiency
Takeda
Phase 3
183
Exeter, Colcester, Gloucester, Cardiff, Milton Keynes, Stafford
2026-01-14
Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
NCT07319871Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 1
40
Manchester, Sutton
2026-01-14
Recruiting
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT07190300Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals
Phase 1/2
181
London
2026-01-13
Active, closed
Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic Variants Causing Severely Debilitating, Life Threatening (SDLT) Central Nervous System (CNS) Conditions
NCT07410143Pediatric SDLT CNS Disorders
EveryONE Medicines Inc.
Phase 1/2
1
London
2026-01-13
Recruiting
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901Obesity With Diabetes, Overweight With Diabetes
Kailera
Phase 3
1,156
Truro, Plymouth, Bournemouth, Hull, Glasgow, London, Stevenage, Leicester
2026-01-12
Recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137Diabetes Mellitus, Type 1
Eli Lilly and Company
Phase 3
150
Birmingham, Cambridge, Cardiff, Glasgow, London, Oxford, Southampton
2026-01-12
Recruiting
ConvaVACโ„ข Ag+ Negative Pressure Wound Therapy System in Chronic Wounds
NCT07342049Venous Leg Ulcer (VLU)
ConvaTec Inc.
Not applicable
87
Bollington, Knutsford, Dorchester, Swaffham, Ashington, Nottingham
2026-01-12
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
AstraZeneca
Phase 1
27
Edinburgh, London
2026-01-09
Recruiting
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
NCT07155226Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes
AstraZeneca
Phase 1/2
84
Edinburgh, London, Manchester, Newcastle
2026-01-09
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
NCT07284459Idiopathic Pulmonary Fibrosis
Contineum Therapeutics
Phase 2
324
Leicester, London, Southampton, Edinburgh, Perth, Birmingham
2026-01-08
Recruiting
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
NCT06904261Fabry Disease
Amicus Therapeutics
Phase 3
8
London, Manchester
2026-01-08
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285Overweight, Obesity
Novo Nordisk A/S
Phase 3
460
Birmingham, Liverpool, London
2026-01-08
By invitation
Lead Evaluation for Defibrillation and Reliability Post Approval Study
NCT07005232Tachyarrhythmia
Medtronic
Observational
2,000
Liverpool, London, Southampton
2026-01-07
Recruiting
Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening
NCT07219277Breast Cancer, Liquid Biopsy, Early Detection
Syantra Inc.
Observational
2,000
Manchester
2026-01-07
Recruiting
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07179380Pulmonary Hypertension, Interstitial Lung Disease
Insmed Incorporated
Phase 3
344
London, Sheffield, Bath, Glasgow, Southampton
2026-01-07
Recruiting
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
NCT07224581GRIN-related Neurodevelopmental Disorder
GRIN Therapeutics, Inc.
Phase 3
100
Sheffield, Glasgow, London
2026-01-05
Recruiting
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07222761Relapsed and/or Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals
Phase 3
915
Aberdeen, Truro, Plymouth, Norwich, Birmingham, Dundee
2026-01-02
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb
Phase 2/3
590
Leicester, London
2026-01-02
Recruiting
Plant-Protein Dominant Tube Feed Study
NCT07422935Enteral Nutrition (Food for Special Medical Purposes), Enteral Feeds
Nutricia UK Ltd
Not applicable
110
Trowbridge
2026-01-01
Recruiting
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
NCT07033598Leukemia, Myelomonocytic, Chronic
Theradex
Phase 2
66
London, Manchester
2026-01-01
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2/3
990
Norwich, Manchester, Metropolitan Borough of Wirral, Oxford, Guildford, Birmingham, Cardiff, Dorchester
2025-12-31
Recruiting
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
NCT07284979Obesity
Kailera
Phase 3
1,200
Exeter, Torquay, Weymouth, Glasgow, London, Leicester, Rotherham
2025-12-30
Recruiting
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
NCT07392255Geographic Atrophy Secondary to Age-related Macular Degeneration
Complement Therapeutics
Phase 1/2
75
London
2025-12-30
Recruiting
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660Atopic Dermatitis
UCB Biopharma SRL
Phase 2
160
London, Salford, Sheffield
2025-12-29
Recruiting
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
NCT07104565Immune Thrombocytopenia
Incyte Corporation
Phase 2
56
Cottingham, London, Plymouth
2025-12-29
Recruiting
A Study to Investigate Bowel Cleansing With PLENVUยฎ Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy
NCT07218523Bowel Cleansing Prior to Clinical Procedures
Norgine
Phase 3
212
Edinburgh, Newcastle upon Tyne, Sheffield, London, Birmingham
2025-12-29
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
AstraZeneca
Phase 3
1,100
Barrow in Furness, Birmingham, Cambridge, Canterbury, Cardiff, Edinburgh, Greater London, London
2025-12-29
By invitation
Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy
NCT07209332Duchenne Muscular Dystrophy
Wave Life Sciences USA, Inc.
Phase 2
175
Headington
2025-12-28
Recruiting
Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet
NCT07251712Healthy
Galmed Pharmaceuticals Ltd
Phase 1
32
London
2025-12-25
Active, closed
Clinical Performance Evaluation of the QIAstat-Dxยฎ cUTI Plus AMR
NCT06824129Complicated Urinary Tract Infection
QIAGEN Gaithersburg, Inc
Observational
1,500
Manchester
2025-12-23
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
800
Edinburgh, Huddersfield, London, Manchester, Plymouth, Worcester
2025-12-22
Recruiting
A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B
NCT07200193Chronic Hepaititis B
nChroma Bio
Phase 1/2
66
London
2025-12-22
Active, closed
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR
Taiho Oncology, Inc.
Phase 3
360
Manchester, Nottingham, Torquay, Cardiff
2025-12-22
Recruiting
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
NCT06717295Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
Javier Toledo
Observational
6,000
Cambridge, London
2025-12-20
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC
Phase 3
800
Cardiff, Glasgow, London, Newcastle upon Tyne, Preston, Sutton
2025-12-19
Recruiting
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
NCT07287982Spinal Muscular Atrophy (SMA)
argenx
Phase 2
60
Cambridge, London, Oxford, Sheffield, Glasgow, Birmingham, Leeds
2025-12-19
Active, closed
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850Obesity and Overweight
Pfizer
Phase 3
3,578
Sandbach, Hendon, Glasgow, Bellshill, Birmingham, Bristol, Bromborough, Edgbaston
2025-12-19
Recruiting
Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clinical Follow-up
NCT07209852Bradycardia, Atrioventricular Block, Sinus Node Dysfunction, Bundle-Branch Block
Boston Scientific Corporation
Observational
140
Redhill
2025-12-19
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic
Vascutek Ltd.
Not applicable
150
London
2025-12-19
Recruiting
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
NCT07287397Amyotrophic Lateral Sclerosis
Vector Y Therapeutics
Phase 1/2
12
London, Sheffield
2025-12-19
Recruiting
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875Obesity, Overweight
Kailera
Phase 3
2,340
Soham, Torpoint, Hull, Stevenage, Leicester, Nottingham, Newcastle upon Tyne, Bradford
2025-12-18
Recruiting
Monitoring Oedema in Heart Failure to Improve Function and Reduce Hospitalisation Risk
NCT07067658Heart Failure
Heartfelt Technologies
Not applicable
300
Aylesbury, Croydon, Welwyn Garden City, Patrington, Ashford, Lincoln, Hardwick, Belfast
2025-12-18
Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia)
NCT07391241Vulvodynia
Initiator Pharma
Phase 2
24
Blackpool
2025-12-17
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
ArriVent BioPharma, Inc.
Phase 3
480
London, Manchester
2025-12-17
Recruiting
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
NCT07194070Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Observational
175
Birmingham
2025-12-17
Recruiting
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 ยตg HFA-152a in Subjects With Mild to Moderate Asthma
NCT07301736Asthma
Chiesi Farmaceutici S.p.A.
Phase 2
780
Belfast, Bristol, Dagenham, London, Maidstone, Manchester, Orpington, Portsmouth
2025-12-17
Recruiting
FeetSee Thermal Images Collection Protocol in Diabetes Patients
NCT07300163Diabetic Foot Ulcer
Diabetis JSC
Observational
100
Blackpool, Lancaster, Manchester
2025-12-16
Recruiting
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
NCT07300969Major Depressive Disorder (MDD)
Draig Therapeutics Ltd
Phase 2
300
Chester, Eastbourne, Glasgow, London, Nottingham, Oxford
2025-12-16
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines, Inc.
Phase 3
500
Birmingham, Glasgow, London, Manchester
2025-12-15
Recruiting
Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.
NCT07243002Breast Cancer
Novartis Pharmaceuticals
Observational
3,000
London
2025-12-15
Recruiting
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
NCT07276581Rheumatoid Arthritis
AstraZeneca
Phase 2
320
Glasgow, Leeds, Luton, Staffordshire
2025-12-15
Recruiting
Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)
NCT07072468Chemotherapy-induced Peripheral Neuropathy, Drug-Induced Nephropathy
VM Therapeutics LLC
Phase 2
16
London
2025-12-12
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
450
Huddersfield, London, Manchester, Sheffield
2025-12-12
Recruiting
A Study to Evaluate ALN-4285 in Adult Healthy Volunteers
NCT07295717Healthy Volunteers
Alnylam Pharmaceuticals
Phase 1
76
London
2025-12-12
Recruiting
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
NCT07062588Osteogenesis Imperfecta (OI)
Angitia Incorporated Limited
Phase 2
80
Cambridge, Edinburgh, London, Oxford
2025-12-12
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.
Phase 3
150
Cardiff, London, Manchester, Sheffield
2025-12-11
Active, closed
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
NCT07228403Short Bowel Syndrome (SBS)
Zealand Pharma
Phase 3
28
Ealing
2025-12-11
Recruiting
Acceptability and Tolerance Study of Bolus Tube Feed With Food Blends
NCT07341464Cerebral Palsy (CP), Oncology
Sociรฉtรฉ des Produits Nestlรฉ (SPN)
Not applicable
50
Nottingham, Worcester
2025-12-10
Recruiting
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559Breast Cancer, Metastatic
ALX Oncology Inc.
Phase 2
120
London, Cardiff, Nottingham
2025-12-10
Recruiting
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
NCT07285213Clostridioides Difficile Infection
AstraZeneca
Phase 2
230
Birmingham, Cambridge, Cardiff, Newcastle
2025-12-10
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer
AbbVie
Phase 2/3
490
London, Manchester
2025-12-10
Recruiting
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
NCT07282665Clostridoides Difficile Associated Disease
Pfizer
Phase 3
32,500
Newquay, Exeter, Plymouth, Torquay, Preston, Glasgow, Southampton, Blackpool
2025-12-10
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
Cybin IRL Limited
Phase 3
330
Cambridge, Doncaster, Edinburgh, Glasgow, London, Newcastle upon Tyne, Reading, Sheffield
2025-12-10
Recruiting
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
NCT07224373Multiple Sclerosis
AstraZeneca
Phase 1
24
Cambridge, London
2025-12-09
Recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEYยฎ Kids)
NCT07107945Chronic Kidney Disease
Boehringer Ingelheim
Phase 3
120
Birmingham, Bristol, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton
2025-12-09
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779Ovarian Cancer
Incyte Corporation
Phase 3
466
Cambridge, Cardiff, Guildford, Leeds, Liverpool, London, Manchester Greater, Northampton
2025-12-09
Active, closed
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants
NCT07286682Healthy Participants
UCB Biopharma SRL
Phase 1
80
Harrow
2025-12-08
Active, closed
Effects of a Multi-Targeted Oral Supplement on Skin, Hair, Sleep, Energy, Cognition, Libido and Epigenetic Biological Clock Age
NCT07827651Skin Ageing, Healthy Ageing, Effect of Oral Nutritional Supplementation on Skin, Hair, Sleep, Energy, Cognition and Sexual Wellbeing in Healthy Adults, Longevity
IDI Skincare Limited
Not applicable
64
Edinburgh
2025-12-08
Recruiting
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases
Satellos Bioscience, Inc.
Phase 2
51
London
2025-12-08
Recruiting
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
NCT07137598Rheumatoid Arthritis
Hoffmann-La Roche
Phase 2
160
Leicester, Doncaster, Newcastle upon Tyne, Barnet
2025-12-05
Active, closed
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
NCT07222917Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 2
222
Dundee, Liverpool, London
2025-12-05
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
AstraZeneca
Phase 3
1,100
Birmingham, Glasgow, Greater London, Leeds, London, Manchester
2025-12-04
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
Merck Sharp & Dohme LLC
Phase 2
150
London, Manchester
2025-12-04
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC
Phase 3
500
Cambridge, Cottingham, Edinburgh, Greater London, Guildford, London, Metropolitan Borough of Wirral, Northwood
2025-12-03
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
GlaxoSmithKline
Phase 3
450
Manchester, Edinburgh, Cambridge, Leeds, London, Sheffield
2025-12-03
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Observational
380
Bath, Cardiff, Eastbourne, Guildford, Heath Town, London, Manchester, Sutton
2025-12-03
Rows per page Showing 301–400 of 2847
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-uk?page=4

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.